German pharmaceutical company Biontech has made progress with a drug for the treatment of lung cancer. Interim results from a phase 1/2 trial show encouraging signs, the company announced Friday.
The data indicated that the drug also works in patients who have had no success with usual treatment. At the same time, the safety profile is verifiable.
The antibody seems to be working as desired
Biontech is collaborating with American manufacturer OncoC4 to develop an antibody against non-small cell lung cancer – a disease in which cells in the lungs divide unhealthyly and form clots. These tumors can affect the normal functioning of the lungs and even spread to other parts of the body, such as other organs or bones.
The two companies are now aiming to initiate a phase 3 trial in the third quarter, which is a condition of approval.
Corona vaccination provided an innovation boost
Lung cancer is the most commonly diagnosed malignant cancer and causes the highest number of cancer-related deaths worldwide. Above all, the corona pandemic has now triggered a wave of innovation that can help with treatment.
Due to the widespread use of mRNA vaccines, hopes are growing that a vaccine against cancer will be on the market in the foreseeable future. Pharmaceutical giant Moderna even wants to do this within the next seven years.
Source: Krone
I am an experienced and passionate journalist with a strong track record in news website reporting. I specialize in technology coverage, breaking stories on the latest developments and trends from around the world. Working for Today Times Live has given me the opportunity to write thought-provoking pieces that have caught the attention of many readers.
